Outcomes of male patients with Alport syndrome undergoing renal replacement therapy.
about
Advances and unmet needs in genetic, basic and clinical science in Alport syndrome: report from the 2015 International Workshop on Alport SyndromeDe novo glomerular diseases after renal transplantationThe Danish Nephrology RegistryOcular features in Alport syndrome: pathogenesis and clinical significanceAnti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathwaysIdentification of microRNAs and their target genes in Alport syndrome using deep sequencing of iPSCs samples.Chronic kidney disease: a new look at pathogenetic mechanisms and treatment options.Alport syndrome from bench to bedside: the potential of current treatment beyond RAAS blockade and the horizon of future therapies.Outcomes of kidney transplantation in Alport syndrome compared with other forms of renal disease.Renal, auricular, and ocular outcomes of Alport syndrome and their current management.The Chemical Chaperone, PBA, Reduces ER Stress and Autophagy and Increases Collagen IV α5 Expression in Cultured Fibroblasts From Men With X-Linked Alport Syndrome and Missense Mutations.End-stage kidney disease due to Alport syndrome: outcomes in 296 consecutive Australia and New Zealand Dialysis and Transplant Registry cases.Genotype and Outcome After Kidney Transplantation in Alport Syndrome.Renal transplantation in patients with Alport syndrome: patient selection, outcomes, and donor evaluation
P2860
Q26748817-009F84A4-6D13-4686-AD20-582E7D9D7ECEQ27005877-3AD67ACD-FCA1-432F-9AD9-E7CE41C951E7Q28079103-ED35DE7A-B0A8-4EBB-8E56-7537F9D3329BQ28080691-72E97929-6A8F-4F98-9760-3D3ED93AB267Q30405346-1E267304-40B1-4947-9736-F212B413868BQ35170636-366E0A48-3EFC-46A4-9B94-B68380C88732Q38087529-A3BC47D7-2BCA-4B90-809A-B58ED8FDEAEEQ38244117-57F69D59-7D3C-4A3D-B5A4-C92830E6D540Q40441782-41F6FEED-2FC2-40A5-A1D2-C453C2A5B79BQ45871465-827497AC-E05B-4BB6-B34B-72A6E28337ACQ47094043-9F492553-7198-4023-9F78-14150BB41300Q51125064-888C06FA-6660-47EA-B38E-85E1C1FC6391Q55081531-92917F8D-88C3-40C6-8168-2D8DBDEE5D46Q58555894-C63A40A0-C5A1-450F-AB2C-04EF7C2F9515
P2860
Outcomes of male patients with Alport syndrome undergoing renal replacement therapy.
description
2012 nî lūn-bûn
@nan
2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Outcomes of male patients with Alport syndrome undergoing renal replacement therapy.
@ast
Outcomes of male patients with Alport syndrome undergoing renal replacement therapy.
@en
Outcomes of male patients with Alport syndrome undergoing renal replacement therapy.
@nl
type
label
Outcomes of male patients with Alport syndrome undergoing renal replacement therapy.
@ast
Outcomes of male patients with Alport syndrome undergoing renal replacement therapy.
@en
Outcomes of male patients with Alport syndrome undergoing renal replacement therapy.
@nl
prefLabel
Outcomes of male patients with Alport syndrome undergoing renal replacement therapy.
@ast
Outcomes of male patients with Alport syndrome undergoing renal replacement therapy.
@en
Outcomes of male patients with Alport syndrome undergoing renal replacement therapy.
@nl
P2093
P2860
P50
P356
P1476
Outcomes of male patients with Alport syndrome undergoing renal replacement therapy
@en
P2093
Andries J Hoitsma
Anna V Reisæter
Anneke Kramer
Faical Jarraya
Gerhard-Anton Müller
James G Heaf
Johanna Temme
Julio P Santos
Katharina Lange
Kitty J Jager
P2860
P304
P356
10.2215/CJN.02190312
P577
2012-09-20T00:00:00Z